National Cancer Institute (NCI) Cancer ClinicalInvestigator Team Leadership Award (CCITLA) P30 Administrative Supplement forFiscal Year (FY) 2021

1.0摘要：总体 我们在马里兰大学马琳和斯图尔特·格林鲍姆综合癌症中心的战略 (UMGCCC)是利用基础癌症生物学的发现，与临床、人口、 和预防研究，以(A)制定和应用创新的癌症治疗和预防战略 患者，(B)描述涉及特定临床表型和行为的分子机制，(C)适用 向马里兰州社区提供特别关注癌症差异的发现和战略，以及(D)提供 为学生、研究员、临床医生和工作人员提供癌症生物学和癌症护理方面的培训。这些策略统称为 将为马里兰州社区癌症中心的临床和研究任务提供服务 未来。在本申请中，UMGCCC寻求癌症中心支持补助金的第二次竞争性续签 (CCSG)，于2008年8月首次授予UMGCCC；#年授予“综合”称号 2016年。在本申请中，UMGCCC由137名正式成员和88名准成员代表，他们在5个研究项目中工作 计划，自我们2015年的申请以来没有变化。该应用程序描述了七个共享服务。UMGCCC 提供了一个有效的结构，以支持这一人才群体的多学科癌症研究活动 调查人员。癌症直接资助总额为7910万美元，其中1420万美元来自国家癌症研究所。 在上一个周期中，对癌症的直接资助增加了70%。2019年，UMGCCC为3095名新癌症患者提供服务 病人。在上一个资助周期中，共有9702名患者参加了临床试验。56%的人 临床试验的参与者是少数族裔，反映了UMGCCC参与临床试验的独特地位和使命 在最先进的临床和翻译研究中的少数族裔社区。这包括48.2% 代表不足的少数族裔和7.8%的亚洲人，后者反映了检查健康的临床试验 在这一群体中存在差异。未被充分代表的少数族裔参加治疗试验的比例为34.7%。UMGCCC 继续为了解癌症生物学做出杰出贡献，并从 UMGCCC实验室和诊所现在是护理或高级临床试验的标准。《美国新闻与世界》 美国癌症项目报告排名连续13年将UMGCCC评为前50名。反思 取得显著和持续的进展，UMGCCC寻求更新其CCSG，以加强和扩大其努力和 支持高质量和临床相关的癌症研究。

1.0 Abstract: Overall Our strategy at the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC) is to take advantage of discoveries in basic cancer biology, in conjunction with clinical, population, and prevention research, to (a) develop and apply innovative therapeutic and preventive strategies to cancer patients, (b) describe the molecular mechanisms involving specific clinical phenotypes and behaviors, (c) apply discoveries and strategies to the Maryland community with a specific focus on cancer disparities, and (d) provide training in cancer biology and cancer care for students, fellows, clinicians, and staff. These strategies collectively will serve the clinical and research missions of the Cancer Center for the Maryland community well into the future. In this application, UMGCCC seeks the second competitive renewal of the Cancer Center Support Grant (CCSG), which was first awarded to UMGCCC in August 2008; “Comprehensive” designation was awarded in 2016. For this application, UMGCCC is represented by 137 full and 88 associate members working in 5 research programs, unchanged since our 2015 application. The application describes seven shared services. UMGCCC provides an effective structure to support the multidisciplinary cancer research activities of this talented group of investigators. Total direct cancer funding is $79.1 million, with $14.2 million from the National Cancer Institute. Direct cancer funding has increased 70 percent in the last cycle. In 2019, UMGCCC served 3,095 new cancer patients. In the last funding cycle, a total of 9,702 patients participated in clinical trials. Fifty-six percent of all participants in clinical trials were minorities, reflecting UMGCCC's unique position and mission to involve the minority community in state-of-the-art clinical and translational research. This includes 48.2 percent underrepresented minorities as well as 7.8 percent Asians, the latter reflecting clinical trials examining health disparities in that group. Underrepresented minority accrual to therapeutic trials is 34.7 percent. UMGCCC continues to make outstanding contributions to understanding cancer biology, and important recent work from UMGCCC labs and clinics is now the standard of care or in advanced clinical trials. The U.S. News & World Report ranking of U.S. cancer programs has named UMGCCC in the top 50 for 13 consecutive years. Reflecting remarkable and continued progress, UMGCCC seeks to renew its CCSG to enhance and expand its efforts and support high-quality and clinically relevant cancer research.